Picture of Immuron logo

IMC — Immuron News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Immuron surges on positive data for diarrhea drug candidate

** U.S.-listed shares of Australia-based drug developer
Immuron more than double to $4.52 in premarket trading    
    ** IMRN says its experimental drug, Travelan, was shown to
be significantly effective in preventing moderate to severe
diarrhea caused by enterotoxigenic Escherichia coli (ETEC)
infection, according to interim data from a mid-stage study
    ** ETEC infection is caused by ingestion of contaminated
food and water and is the most common illness reported by
travelers visiting developing countries and among U.S. troops
deployed overseas
     ** A single dose of the Travelan showed 36.4% protective
efficacy against ETEC-induced moderate to severe diarrhea
compared to placebo - Co 
    ** Co expects to report final data in H2 2024 
    ** Says IMRN is exploring non-dilutive funding opportunities
for late-stage studies of the drug
    ** Up to last close, U.S.-listed stock down 19% in the last
12 months

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))

Recent news on Immuron

See all news